Oral eplerenone for treatment of chronic central serous chorioretinopathy : a case series

Copyright 2015, SLACK Incorporated.

Détails bibliographiques
Publié dans:Ophthalmic surgery, lasers & imaging retina. - 2013. - 46(2015), 4 vom: 13. Apr., Seite 439-44
Auteur principal: Salz, David A (Auteur)
Autres auteurs: Pitcher, John D 3rd, Hsu, Jason, Regillo, Carl D, Fineman, Mitchell S, Elliott, Kevin S, Vander, James F, Fischer, David H, Spirn, Marc J
Format: Article en ligne
Langue:English
Publié: 2015
Accès à la collection:Ophthalmic surgery, lasers & imaging retina
Sujets:Journal Article Mineralocorticoid Receptor Antagonists Spironolactone 27O7W4T232 Eplerenone 6995V82D0B
Description
Résumé:Copyright 2015, SLACK Incorporated.
BACKGROUND AND OBJECTIVE: To evaluate the effect of oral eplerenone on subretinal fluid, visual acuity, and choroidal thickness in patients with chronic central serous chorioretinopathy (CSCR)
PATIENTS AND METHODS: Retrospective review of all patients (14 eyes of 14 patients) monitored for a minimum of 3 months with chronic CSCR who were treated with oral eplerenone in a single multi-physician retina practice. Visual acuity, dilated funduscopic examination, and spectral-domain ocular coherence tomography (OCT) with enhanced depth imaging (EDI) were obtained at each visit. Measurement of subfoveal fluid (SFF) height and choroidal thickness were performed. Two-tailed paired t test was used to calculate statistical significance of pre- and post-treatment variables
RESULTS: At 1 month, 10 of 14 eyes had decreased SFF height on OCT and two eyes had complete resolution of SFF. Mean SFF height decreased from 130 µm to 62 µm (P = .05). Mean choroidal thickness decreased from 315 µm to 282 µm (P = .07). Mean visual acuity improved from logMAR 0.41 to 0.40. At 3 months, 13 of 14 (93%) had decreased SFF on OCT, and nine eyes (64%) had complete resolution of SFF. Mean SFF height decreased to 21 µm (P = .004). Mean choroidal thickness decreased to 253 µm (P = .10). Mean visual acuity improved to logMAR 0.28 (P = .02)
CONCLUSION: Oral eplerenone may be effective in treating patients with chronic CSCR
Description:Date Completed 23.10.2015
Date Revised 10.04.2022
published: Print
Citation Status MEDLINE
ISSN:2325-8179
DOI:10.3928/23258160-20150422-06